Please login to the form below

Not currently logged in


This page shows the latest ABT-450 news and features for those working in and with pharma, biotech and healthcare.

AbbVie closes in on US approval of all-oral hepatitis C regimen

FDA grants priority review to company’s protease inhibitor ABT-450 regimen. The US FDA has granted priority review to AbbVie's all-oral regimen for the treatment of adult patients ... The regimen consists of the protease inhibitor ABT-450 boosted by

Latest news

More from news
Approximately 1 fully matching, plus 8 partially matching documents found.

Latest from PMHub

  • Warehousing of HCV patients reaches new high

    However, Abbvie’s products ABT 267, ABT 333 and ABT 450 remain contenders for market share, scoring higher than J&J’s simeprevir in terms of likelihood to prescribe amongst doctors

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...